ADVA
11.9.2019 09:02:11 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Inoventica has selected its FSP 3000 platform to meet soaring data demand from enterprise and carrier customers. Inoventica, one of Russia’s leading IT service providers and data center operators, will leverage the solution to boost the capacity of its backbone network to 100Gbit/s and beyond. The new fully redundant infrastructure leverages ADVA’s QuadFlex™ line card and OpenFabric™ cross-connect – two technologies optimized for efficiency and complete flexibility. ADVA’s Select partner, the IT solution specialist Zettaline is also playing a key role in facilitating the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190911005024/en/
“ADVA’s technology enables us to take the next step with our infrastructure while also leveraging maximum value from our existing network. With this deployment, we can flexibly respond to soaring data requirements and help our customers to unleash their full potential,” said Vitaly Slizen, CEO, Inoventica. “The ADVA FSP 3000 delivers several key efficiencies from low latency to optimized bandwidth utilization. And the FSP 3000 OpenFabric™ empowers us to cost-effectively provide the data rates our customers need by aggregating 1Gbit/s and 10Gbit/s services onto 100Gbit/s wavelengths. Furthermore, its openness means we can reap the benefits of unlimited innovation cycles in the future.”
Designed for scalability and bandwidth optimization, the ADVA FSP 3000 ensures that Inoventica’s new infrastructure offers superb efficiency. It enables significant energy savings and, with its 1RU footprint, occupies very little rack space. Using ADVA FSP 3000 QuadFlex™ technology, the solution will transport 100Gbit/s data loads over distances stretching to 2,000km across the Moscow metropolitan area. By enabling greater spectral efficiency, QuadFlex™ delivers extended reach without any need for signal regeneration. Also key is the ADVA FSP 3000 OpenFabric™ , which creates a distributed architecture, enabling Inoventica to simply and efficiently aggregate lower-speed services.
“We’re proud that Russia’s largest cloud service provider has chosen to harness our technology and expertise. Together with our partner Zettaline, we’ve built a solution that efficiently expands Inoventica’s infrastructure and provides the tools it needs to address today’s key challenges,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “The new fully redundant solution is protected, flexible and extremely cost-efficient. It also meets all of Inoventica’s density, security and energy requirements. Furthermore, thanks to the modular, scalable design of our FSP 3000 platform and the ongoing support of our team, Inoventica is free to plan an exciting roadmap for further development in the future.”
“This deployment is going to bring substantial benefits to a great number of Russian enterprises and we’re proud to be playing such a big part in helping Inoventica take this leap forward. Working closely with our friends at ADVA, we’ve created a transport system that squeezes maximum value from Inoventica’s existing resources while enabling the flexibility and capacity necessary for the 5G and IoT era,” said Alexander Hochmuth, shareholder representative, Zettaline Ltd. “As a team, ADVA and Zettaline provide both global knowledge and local expertise. Together, we’ve designed an open, disaggregated and completely future-proof solution that meets all of Inoventica’s needs and ambitions.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com .
About Inoventica
INOVENTICA Group of Companies is the first Russian IT-operator that has been implementing projects based on innovative ICT Infrastructure of international scale based on cloud computing technologies since 1999. Partners and clients of the INOVENTICA Group of Companies are more than 5 thousand B2C subscribers, more than 1000 corporate clients (B2B), 48 national and international telecom operators. www.invs.ru
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190911005024/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom